Debra Patt, MD, PhD, MBA, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer research, serves on the US Oncology Research Breast Cancer Committee, and chairs the breast cancer subsection of the pathways task force for The US Oncology Network. Dr. Patt has expertise in healthcare policy and has testified before Congress to protect access to care for Medicare beneficiaries. She is a leader in clinical cancer informatics, and is involved in system innovations to enhance care delivery across a national network of oncology practices.
Dr. Patt serves on the national board for the Community Oncology Alliance and local board of the Shivers Cancer Foundation. She is a nationally recognized leader in cancer research, has published many articles, and leads the service line for breast health services for the Dell Medical School.
Ray D. Page, DO, PhD, FACOI, FASCO, has practiced medical oncology for 23 years. He is President of The Center for Cancer and Blood Disorders, and has been at the forefront of community oncology practice transformation participating in a variety of payment reform models and development of pathway systems. As Director of Research for The Center for Cancer and Blood Disorders, Dr. Page has been the Principal Investigator of over 200 clinical trials and is well published on a variety of cancer-related topics. He has a particular interest in healthcare policy and was recently acknowledged as the American Society of Clinical Oncology (ASCO) Advocate of the Year.
Dr. Page actively serves ASCO, including as the current Chair of the Clinical Practice Committee, Nominating Committee, Government Relations Committee, ASCO Delegate to the AMA House of Delegates, and State Affiliate Council past chair. He has contributed to the publication of several ASCO Policy statements on Pathways, 340B, Site-Neutrality, Safe Handling of Hazardous Drugs, and ASCO’s Patient Centered Oncology Payment model.
Eric Bernicker, MD, completed his medical training, a residency in internal medicine, and a fellowship in hematology at Baylor College of Medicine. He also completed a fellowship in medical oncology at MD Anderson Cancer Center. The goal of Dr. Bernicker's practice is to make sure that his patients get the best available treatments in a compassionate environment.
Dr. Bernicker is the primary investigator for a number of cooperative group, industry-sponsored, and investigator-initiated trials looking at different novel therapies for lung cancer, including immunotherapy. His main clinical focus is on solid tumor oncology, specifically cancers that arise in the thorax such as lung cancer, mesothelioma, head, and neck cancer, and uveal melanomas. He is also interested in targeted therapy for specific mutations that can lead to more personalized treatments for patients battling cancer.
Dr. Bernicker is an assistant clinical professor of medicine at Weill Cornell Medicine, chairman of the Houston Methodist Hospital Cancer Committee, and the liaison for the American Society of Clinical Oncology's quality program, Quality Oncology Practice Initiative. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.
Luis T. Campos, MD, is a member of the American Association for Cancer Research, American Medical Association, American Society of Clinical Oncology, Texas Medical Association, Harris County Medical Society, Fort Bend Medical Society, MD Anderson Associates, and the Peruvian American Medical Society.
Anish Meerasahib, MA, MD, earned his medical degree from the University of Kerala in India and completed a master’s degree in exercise physiology at the University of Maryland in College Park. He then completed his internship and residency training at Drexel University College of Medicine in Philadelphia, followed by a fellowship in hematology/oncology at Georgetown University Hospital in Washington, D.C. During his fellowship, Dr. Meerasahib spent time at the National Institute of Health in Bethesda, Maryland, where he received training in bone marrow transplantation. He has participated in clinical research and published articles in the fields of lymphoma, transplantation, genitourinary cancers, and cancer fatigue.
Ruben Mesa, MD, is the director of UT Health San Antonio MD Anderson Cancer Center, one of only four National Cancer Institute-designated cancer centers in Texas.
Dr. Mesa’s practice builds on his role as an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network’s panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials, and co-led the research team leading to the FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis. Dr. Mesa was elected to sit on the National Board of Directors for the Leukemia and Lymphoma Society and sits on the board of the MPN Education Foundation.
After earning degrees in nuclear engineering and physiology, with minors in radiation biophysics and bioengineering, from the University of Illinois at Urbana-Champaign, Dr. Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in hematology and medical oncology.
Sucharu Prakash, MD, currently serves on the Texas Medical Association (TMA) Committee on Cancer. The committee supervises TMA’s cancer-related activities, educates physicians and patients about cancer, and works with other groups on cancer-related care and issues. As an oncology expert serving on the committee, Dr. Prakash can speak to cancer prevention and risk education, screenings and early detection, diagnosis, treatment, quality of life, and survivorship.
In addition to his TMA involvement, Dr. Prakash also serves on the board of directors for Texas Oncology and is the regional medical director in the Paris, Mount Pleasant, and Greenville areas. He is the principal investigator for research trials at Texas Oncology – Paris, and is a member of the US Oncology Breast Cancer Research Committee.
Alti Rahman, MHA, MBA, is the practice administrator for Oncology Consultants in Houston, Texas, and and is a Certified Six Sigma Black Belt.
Alti has served as faculty speaker and advisor for multiple advisory boards, and holds multiple supplementary roles including: Six Sigma course instructor for Medical Group Management Association, steering committee board member for McKesson Specialty Health, treasurer for the National Cancer Care Alliance, and board member of the Oncology Circle Advisory.
Luis Carlos Rodriguez, MD, received his medical degree from the University of Texas Health Science Center at San Antonio in 1997, after which he was awarded membership to the Alpha Omega Alpha Honor Medical Society. Dr. Rodriguez completed his internal medicine internship, residency, and fellowship in medical oncology and hematology at Barnes Jewish Hospital in St. Louis.
Dr. Rodriguez began private practice in medical oncology and hematology in San Antonio in July of 2003, and has a special interest in managing gastrointestinal malignancies and breast cancer.